Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Mar;70(3):1505-11.
doi: 10.1128/JVI.70.3.1505-1511.1996.

Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice

Affiliations

Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice

G M Aldrovandi et al. J Virol. 1996 Mar.

Abstract

The functional roles of the human immunodeficiency virus type 1 (HIV-1) accessory genes (nef, vpr, vpu, and vif) are as yet unclear. Using the SCID-hu model system, we have examined the infectivity, replicative capacity, and pathogenicity of strains of the molecular clone HIV-1NL4-3 that contain deletion mutations in these individual accessory genes. We determined that deletion of these genes had differential effects on both infectivity and pathogenicity. Deletion of vpr had little or no effect on viral infectivity, replication, and pathogenicity; however, deletion of vpu or vif had a significant effect on infectivity and moderate effects on pathogenicity. nef-minus strains were the most attenuated in this system, demonstrating significantly lower levels of infectivity and pathogenicity. However, deletion of these individual genes attenuated but did not abrogate the pathogenic properties of HIV-1. Mutant viruses still retained the ability to induce thymocyte depletion to various degrees if implants were infected with higher doses of virus or observed for longer periods of time. The relative contributions of these genes to in vivo pathogenic potential should be taken into consideration when one is contemplating a live attenuated vaccine for HIV-1.

PubMed Disclaimer

References

    1. Cell. 1991 May 17;65(4):651-62 - PubMed
    1. Cell. 1990 Apr 20;61(2):213-22 - PubMed
    1. Pediatrics. 1992 Feb;89(2):297-301 - PubMed
    1. J Virol. 1992 Mar;66(3):1717-25 - PubMed
    1. J Virol. 1992 Oct;66(10):6213-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources